Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              XWPharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO Digital 2021

              Participation Not Confirmed

              Update your events

              XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer

              Contact the Supplier

              Lead Product(s): XW10172

              Therapeutic Area: Sleep Product Name: XW10172

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Panacea Venture

              Deal Size: $40.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing September 17, 2020

              Details:

              XWPharma expects to use proceeds to advance clinical development of the company’s lead investigational programs: XW10172, a GABAB receptor agonist intended for the treatment of sleep disorders in narcolepsy, Parkinson’s disease and other neurodegenerative diseases.

              Imbrium Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO Digital 2021

              Participation Not Confirmed

              Update your events

              Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115

              Contact the Supplier

              Lead Product(s): IMB-115

              Therapeutic Area: Sleep Product Name: IMB-115

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 28, 2020

              Details:

              IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor impairment.

              PharmaCompass__DigitalAd